bioAffinity Technologies Reports Record Third-Quarter 2025 Growth in CyPath® Lung Test Adoption, Driven by Expanding Clinical Use and Physician Confidence bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company pioneering noninvasive diagnostics for lung cancer and other lung diseases, has…
TCGX Closes Oversubscribed $1.3 Billion Fund III, Strengthening Its Position in Global Biopharma Investment TCG Crossover (“TCGX”), a leading global investment firm focused on the biotechnology and life sciences sector, announced the successful close of its third fund—TCGX Fund III—with…
Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares Alpha Cognition Inc. (Nasdaq: ACOG) (the “Company”), a commercial-stage biopharmaceutical company committed to advancing innovative therapies for neurodegenerative diseases, today announced the pricing of its oversubscribed…
GSK Commits $30B To Boost US R&D, Manufacturing Operations The multi-billion, multi-year investment comes as many of GSK’s pharma peers pull away from the U.K., either suspending or completely canceling previous commitments.GSK will pump $30 billion into the U.S. over…
Choosing China: Akeso’s $3M Beginnings and the Rise of China’s Biotech Sector When Akeso was starting out some 13 years ago, the leadership team had $3 million and a bold goal to move China’s drug industry toward innovation. When Akeso…
Pioneering sustainable transatlantic transport to cut emissions in pharmaceutical supply chains Takeda (TSE:4502/NYSE:TAK) and VELA Transport today announced their business partnership, with Takeda set to become the first biopharmaceutical company to transport its products between Europe and the U.S. using…
Sanofi Joins Growing Group of Pharmas Pulling Back From UK Merck, Eli Lilly and AstraZeneca have similarly suspended or outright canceled investments in the U.K. in the past week after a sizeable increase in a mandatory levy in the region…
Royalty Pharma and Deloitte Release Landmark Study on the Role of Royalties in Funding Biopharma Innovation Royalty Pharma plc (Nasdaq: RPRX), the world’s largest acquirer of biopharmaceutical royalties and a key investor in life sciences innovation, has announced the publication…
Alnylam Pharmaceuticals Prices Upsized $575 Million Convertible Senior Notes Offering, Strengthening Balance Sheet and Advancing Growth Strategy Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a recognized global leader in RNA interference (RNAi) therapeutics, has announced the successful pricing of its private offering…
Cascade Bio Secures $6 Million to Advance Biocatalyst Innovation and Transform Biomanufacturing In a world grappling with climate change, supply chain disruptions, and the growing demand for sustainable manufacturing, biotechnology companies are racing to create alternatives to petrochemical-based production. Cascade…
JCR Pharmaceuticals Showcases Landmark Five-Year Clinical Data on Pabinafusp Alfa at ICIEM 2025, Reinforcing Transformative Potential for Patients with Hunter Syndrome and Expanding Pipeline of Brain-Penetrant Enzyme Replacement Therapies In early September 2025, the city of Kyoto, Japan, became the…
Roche’s Vabysmo Reinforces Long-Term Benefits in Wet Age-Related Macular Degeneration and Shows Strong Gains in Polypoidal Choroidal Vasculopathy Paris, France – At the 25th annual Euretina Congress, one of the world’s most important scientific gatherings focused on retinal disease, Roche…